Skip to main content
TipRanks
Go Ultimate75% OFF

CalciMedica (CALC) AI Stock Analysis

319 Followers
CALC

CalciMedica

(NASDAQ:CALC)

Select Model
Rating:43Neutral
Price Target:$1.00â–¼(-18.03% Downside)
Action:reiterated
Date:11/13/26

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and substantial cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Corporate events modestly offset risk through restored Nasdaq compliance, but financing actions (ATM/equity issuances and reverse split) reinforce dilution and funding dependence, while valuation metrics offer limited support due to losses and no dividend.

Positive Factors
Low leverageThe absence of debt reduces near-term interest and refinancing pressure, while positive equity provides some balance-sheet support for ongoing development. This gives CalciMedica greater financial flexibility than a similarly loss-making biotech carrying material leverage.
Negative Factors
No commercial revenueThe absence of commercial revenue leaves CalciMedica dependent on successful clinical and regulatory progress before it can become self-funding. Continued operating losses also make future earnings uncertain and increase the financial consequences of delays or unsuccessful development.

CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%CALC-92.58%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.84M
Dividend Yield
―
Average Volume (3M)
81.66K
Price to Earnings (P/E)
-0.3
Beta (1Y)
0.13
Revenue Growth
―
EPS Growth
45.29%
Country
US
Employees
16
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

CalciMedica Business Overview & Revenue Model

Company Description

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach i...

CalciMedica Financial Statement Overview

Summary

Financial profile is weak for profitability and cash generation: TTM shows no revenue, continued losses (net loss ~$15.1M), and significant cash burn (operating and free cash flow about -$18.2M). Balance sheet leverage is low (no debt) with positive equity (~$4.2M), but equity has been volatile historically, and ongoing losses increase reliance on external funding.

Income Statement

12Very Negative

Balance Sheet

38Negative

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-7,0000000-519.00K
EBITDA-13.76M-28.09M-13.64M-34.19M-7.64M-35.30M
Net Income-15.11M-29.56M-13.70M-34.36M-7.82M-35.82M
Balance Sheet
Total Assets14.29M13.59M19.79M12.19M3.35M69.09M
Cash, Cash Equivalents and Short-Term Investments13.77M13.02M18.67M11.24M1.33M63.67M
Total Debt09.70M005.36M0
Total Liabilities10.07M20.23M5.38M4.03M12.58M4.07M
Stockholders Equity4.23M-6.64M14.41M8.16M-9.23M65.02M
Cash Flow
Free Cash Flow-18.20M-21.21M-21.15M-25.81M-11.76M-31.99M
Operating Cash Flow-18.19M-21.18M-21.15M-25.73M-11.76M-31.50M
Investing Cash Flow-453.00K9.55M-4.42M8.88M-4,00010.75M
Financing Cash Flow17.75M15.21M27.97M20.90M8.48M695.00K

CalciMedica Technical Analysis

Technical Analysis SentimentNegative
Last Price1.22

Price Trends

50DMA1.50Negative
100DMA2.52Negative
200DMA2.95Negative

Market Momentum

MACD-0.08Positive
RSI42.48Neutral
STOCH14.12Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Negative. The current price of 1.22 is below the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.50, and below the 200-day MA of 2.95, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CALC.

CalciMedica Risk Analysis

CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.If we are unable to maintain our listing on Nasdaq, it could become more difficult to sell our common stock in the public market.Q4, 2023
2.Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our proprietary platform or product candidates.Q4, 2023
3.Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.Q4, 2023

CalciMedica Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CALC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CALCCALC43Neutral$8.41M-0.27-3029.57%――45.29%
LTRNLTRN42Neutral$5.45M-0.24-456.35%――32.93%
PDSBPDSB42Neutral$93.85M-1.61-559.99%――32.24%
SKYESKYE40Underperform$4.42M-0.13-503.95%――26.40%
SNTISNTI39Underperform$8.31M-0.073547.64%――56.67%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%CALCPDSBSKYELTRNSNTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CALC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CALCCalcimedica, Inc.1.22-14.58-92.28%
PDSBPds Biotechnology0.890.1418.12%
SKYESkye Bioscience, Inc.1.00-9.00-90.00%
LTRNLantern Pharma, Inc.0.36-2.63-87.83%
SNTISenti Biosciences, Inc.0.10-1.71-94.64%

CalciMedica Corporate Events

Executive/Board ChangesRegulatory Filings and Compliance

CalciMedica Announces CFO Resignation and Leadership Transition

Neutral
Oct 16, 2026

On October 15, 2026, CalciMedica, Inc. announced that Chief Financial Officer and principal accounting officer Stephen Bardin submitted his resignation, effective immediately after the filing of the company’s Quarterly Report on Form 10-Q for the qua...

Private Placements and FinancingRegulatory Filings and Compliance

CalciMedica Establishes $25 Million ATM Stock Program

Positive
Sep 30, 2026

On September 30, 2026, CalciMedica filed a prospectus supplement with the Securities and Exchange Commission to enable sales of up to $25 million of its common stock under an existing at-the-market offering agreement with H.C. Wainwright & Co. This f...

Delistings and Listing ChangesRegulatory Filings and Compliance

CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized

Positive
Sep 16, 2026

On March 16, 2026, CalciMedica received a notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, putting the company out of compliance with Listing Rule 5550(a)(2). The company was give...

Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and ComplianceStock Split

CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk

Negative
Sep 2, 2026

On August 31, 2026, CalciMedica reported that Nasdaq staff determined the company now satisfies the alternative minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), based on its June 30, 2026 Form 10-Q showing $5.513 million in equ...

Regulatory Filings and ComplianceShareholder MeetingsStock Split

CalciMedica Announces One-for-Five Reverse Stock Split

Neutral
Aug 27, 2026

On August 27, 2026, CalciMedica filed an amendment to its certificate of incorporation in Delaware to implement a one-for-five reverse stock split and reduce its authorized common shares from 500,000,000 to 100,000,000, effective at 5:00 p.m. Eastern...

Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split

CalciMedica Shareholders Approve Key Equity and Governance Changes

Positive
Aug 20, 2026

On August 19, 2026, CalciMedica held its 2026 annual meeting of stockholders, where investors approved an amendment to the 2023 Equity Incentive Plan, increasing available shares by 7,500,000 and broadening the automatic share reserve calculation to...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026